The development of anti-PD-1, anti-programmed cell death-ligand 1 (PD-L1), and anti-CTLA-4 monoclonal antibodies has advanced the treatment for advanced cancer, resulting in numerous attempts to apply ICIs for the treatment of multiple advanced solid malignancies, including HCC. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.